Proteomic analysis of serum from patients with major depressive disorder to compare their depressive and remission statuses

Psychiatry Investigation

Volumn 12, Issue 2, 2015, Pages 249-259

  Lee, Jiyeong ^a   Joo, Eun Jeong ^a   Lim, Hee Joung ^b   Park, Jong Moon ^c   Lee, Kyu Young ^a   Park, Arum ^a   Seok, AeEun ^a   Lee, HooKeun ^c   Kang, Hee Gyoo ^a  

^a Eulji University   (South Korea)

^b Korea University   (South Korea)

^c Gachon University   (South Korea)

Author keywords

Biomarker; Inflammation; Major depressive disorder; Neurotransmitter; Proteomics

Indexed keywords

ALPRAZOLAM; APOLIPOPROTEIN C3; CERULOPLASMIN; COMPLEMENT COMPONENT C1Q; ESCITALOPRAM; IMMUNOGLOBULIN J CHAIN; INTER ALPHA TRYPSIN INHIBITOR; KALLIKREIN; PLASMA PROTEIN; TRYPSIN; ZOLPIDEM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BECK DEPRESSION INVENTORY; BIOINFORMATICS; BLOOD ANALYSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL ELECTROPHORESIS; HAMILTON DEPRESSION RATING SCALE; HAMILTON DEPRESSION RATING SCALE 17; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR DEPRESSION; MALE; MIDDLE AGED; OFFGEL ELECTROPHORESIS; PRINCIPAL COMPONENT ANALYSIS; PROTEIN ANALYSIS; PROTEIN DATABASE; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; REMISSION; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

EID: 84928266711     PISSN: 17383684     EISSN: 19763026     Source Type: Journal    
DOI: 10.4306/pi.2015.12.2.249     Document Type: Article

References (47)

1. Spijker S, Van Zanten JS, De Jong S, Penninx B, van Dyck R, Zitman FG, et al. Stimulated gene expression profiles as a blood marker of major depressive disorder. Biol Psychiatry 2010;68:179-186.
2. Zhang L, Su TP, Choi K, Maree W, Li CT, Chung MY, et al. P11 (S100A10) as a potential biomarker of psychiatric patients at risk of suicide. J Psychiatr Res 2011;45:435-441.
3. Rossler W, Salize HJ, van Os J, Riecher-Rossler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005;15: 399-409.
4. Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 1997;18:533-537.
5. Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, Shiraishi T, et al. Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. Plos One 2012;7:e42676.
6. Kurita M, Nishino S, Kato M, Numata Y, Sato T. Plasma brain-derived neurotrophic factor levels predict the clinical outcome of depression treatment in a naturalistic study. Plos One 2012;7:e39212.
7. Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry 2014;19:791-800.
8. Jeon HJ, Kang ES, Lee EH, Jeong EG, Jeon JR, Mischoulon D, et al. Childhood trauma and platelet brain-derived neurotrophic factor (BDNF) after a three month follow-up in patients with major depressive disorder. J Psychiatr Res 2012;46:966-972.
9. Yang L, Zhang Z, Sun D, Xu Z, Zhang X, Li L. The serum interleukin-18 is a potential marker for development of post-stroke depression. Neurol Res 2010;32:340-346.
10. Prossin AR, Koch AE, Campbell PL, McInnis MG, Zalcman SS, Zubieta JK. Association of plasma interleukin-18 levels with emotion regulation and mu-Opioid neurotransmitter function in major depression and healthy volunteers. Biol Psychiatry 2011;69:808-812.
11. Kim B, Kang ES, Fava M, Mischoulon D, Soskin D, Yu BH, et al. Follicle-stimulating hormone (FSH), current suicidal ideation and attempt in female patients with major depressive disorder. Psychiatry Res 2013; 210:951-956.
12. Baek JH, Kang ES, Fava M, Mischoulon D, Nierenberg AA, Lee D, et al. Thyroid stimulating hormone and serum, plasma, and platelet brainderived neurotrophic factor during a 3-month follow-up in patients with major depressive disorder. J Affect Disord 2014;169:112-117.
13. Rotilio D, Della Corte A, D’Imperio M, Coletta W, Marcone S, Silvestri C, et al. Proteomics: bases for protein complexity understanding. Thromb Res 2012;129:257-262.
14. Xu HB, Zhang RF, Luo D, Zhou Y, Wang Y, Fang L, et al. Comparative proteomic analysis of plasma from major depressive patients: identification of proteins associated with lipid metabolism and immunoregulation. Int J Neuropsychopharmacol 2012;15:1413-1425.
15. Wilkins MR, Pasquali C, Appel RD, Ou K, Golaz O, Sanchez JC, et al. From proteins to proteomes: large scale protein identification by twodimensional electrophoresis and amino acid analysis. Biotechnology (NY)1996;14:61-65.
16. Martins-de-Souza D. Comprehending depression through proteomics. Int J Neuropsychopharmacol 2012;15:1373-1374.
17. Brinton LT, Brentnall TA, Smith JA, Kelly KA. Metastatic biomarker discovery through proteomics. Cancer Genomics Proteomics 2012;9:345355.
18. Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, Cotter D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for disease-associated changes. Proteomics 2006;6: 3414-3425.
19. Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF, et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry 2000;5:142149.
20. Martins-de-Souza D, Guest PC, Harris LW, Vanattou-Saifoudine N, Webster MJ, Rahmoune H, et al. Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Transl Psychiatry 2012;2:e87.
21. Herberth M, Koethe D, Levin Y, Schwarz E, Krzyszton ND, Schoeffmann S, et al. Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival. Proteomics 2011;11:94105.
22. Raedler TJ, Wiedemann K. CSF-studies in neuropsychiatric disorders. Neuro Endocrinol Lett 2006;27:297-305.
23. Paige LA, Mitchell MW, Krishnan KRR, Kaddurah-Daouk R, Steffens DC. A preliminary metabolomic analysis of older adults with and without depression. Int J Geriatr Psychiatry 2007;22:418-423.
24. Ditzen C, Tang N, Jastorff AM, Teplytska L, Yassouridis A, Maccarrone G, et al. Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology. Neuropsychopharmacology 2012;37:1013-1025.
25. Vassiliev V, Harris ZL, Zatta P. Ceruloplasmin in neurodegenerative diseases. Brain Res Brain Res Rev 2005;49:633-640.
26. Waggoner DJ, Bartnikas TB, Gitlin JD. The role of copper in neurodegenerative disease. Neurobiol Dis 1999;6:221-230.
27. Kakimoto Y, Ito S, Abiru H, Kotani H, Ozeki M, Tamaki K, et al. Sorbin and SH3 domain-containing protein 2 is released from infarcted heart in the very early phase: proteomic analysis of cardiac tissues from patients. J Am Heart Assoc 2013;2:e000565.
28. Licker V, Turck N, Kovari E, Burkhardt K, Cote M, Surini-Demiri M, et al. Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson’s disease pathogenesis. Proteomics 2014;14: 784-794.
29. Marchetti C. Interaction of metal ions with neurotransmitter receptors and potential role in neurodiseases. Biometals 2014;27:1097-1113.
30. Maes M, Scharpe S, Van Grootel L, Uyttenbroeck W, Cooreman W, Cosyns P, et al. Higher alpha 1-antitrypsin, haptoglobin, ceruloplasmin and lower retinol binding protein plasma levels during depression: further evidence for the existence of an inflammatory response during that illness. J Affect Disord 1992;24:183-192.
31. Joyce PR, Hawes CR, Mulder RT, Sellman JD, Wilson DA, Boswell DR. Elevated levels of acute phase plasma proteins in major depression. Biol Psychiatry 1992;32:1035-1041.
32. Borsos T. Immune complex mediated activation of the classical complement pathway. Behring Inst Mitt 1989;(84):93-101.
33. Shalev H, Serlin Y, Friedman A. Breaching the blood-brain barrier as a gate to psychiatric disorder. Cardiovasc Psychiatry Neurol 2009;2009: 278531.
34. Mayilyan KR, Arnold JN, Presanis JS, Soghoyan AF, Sim RB. Increased complement classical and mannan-binding lectin pathway activities in schizophrenia. Neurosci Lett 2006;404:336-341.
35. Lynch NJ, Willis CL, Nolan CC, Roscher S, Fowler MJ, Weihe E, et al. Microglial activation and increased synthesis of complement component C1q precedes blood-brain barrier dysfunction in rats. Mol Immunol 2004;40:709-716.
36. Gonzalez-Ramon N, Alava MA, Sarsa JA, Pineiro M, Escartin A, Garcia Gil A, et al. The major acute phase serum potein in pigs is homologous to human plasma kallikrein sensitive PK-120. FEBS Lett 1995;371:227230.
37. Pineiro M, Alava MA, Gonzalez-Ramon N, Osada J, Lasierra P, Larrad L, et al. ITIH4 serum concentration increases during acute-phase processes in human patients and is up-regulated by interleukin-6 in hepatocarcinoma HepG2 cells. Biochem Biophys Res Commun 1999;263:224229.
38. Choi-Miura NH. Quantitative measurement of the novel human plasma protein, IHRP, by sandwich ELISA. Biol Pharm Bull 2001;24:214-217.
39. Sluzewska A, Sobieska M, Rybakowski JK. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology 1997;35:123-127.
40. Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 1997;66:1-11.
41. Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M, et al. Indicators of immune activation in major depression. Psychiatry Res 1996;64:161-167.
42. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009;71: 171-186.
43. Tochigi M, Iwamoto K, Bundo M, Sasaki T, Kato N, Kato T. Gene expression profiling of major depression and suicide in the prefrontal cortex of postmortem brains. Neurosci Res 2008;60:184-191.
44. Loeffler DA, Sima AAF, LeWitt PA. Ceruloplasmin immunoreactivity in neurodegenerative disorders. Free Radic Res 2001;35:111-118.
45. Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH, et al. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol Psychiatry 2013;18:332-339.
46. Le-Niculescu H, Kurian SM, Yehyawi N, Dike C, Patel SD, Edenberg HJ, et al. Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry 2009;14:156-174.
47. Wiederin J, Rozek W, Duan FH, Ciborowski P. Biomarkers of HIV-1 associated dementia: proteomic investigation of sera. Proteome Sci 2009; 7:8.